Development and Evaluation of a Sarcocystis neurona-Specific IgM Capture Enzyme-Linked Immunosorbent Assay

• Published in: Journal of veterinary internal medicine 2006-03, Vol.20 (2), p.322-328
• Main Authors: Murphy, J.E., Marsh, A.E., Reed, S.M., Meadows, C., Bolten, K., Saville, W.J.A.
• Format: Article
• Language: English
• Subjects: Animals; Diagnosis; Enzyme-Linked Immunosorbent Assay - methods; Enzyme-Linked Immunosorbent Assay - veterinary; Equine; Horse Diseases - blood; Horse Diseases - cerebrospinal fluid; Horse Diseases - diagnosis; Horse Diseases - parasitology; Horses; Immunoglobulin M - analysis; Immunoglobulin M - blood; Immunoglobulin M - cerebrospinal fluid; Immunoglobulin M - immunology; Myeloencephalitis; Protozoal; Sarcocystis - immunology; Sarcocystis neurona; Sarcocystosis - blood; Sarcocystosis - cerebrospinal fluid; Sarcocystosis - diagnosis; Sarcocystosis - veterinary; Sensitivity and Specificity; Time Factors
• ISSN: 0891-6640; 1939-1676
• DOI: 10.1111/j.1939-1676.2006.tb02863.x

Equine protozoal myeloencephalitis (EPM) is a serious neurologic disease of horses caused primarily by the protozoal parasite Sarcocystis neurona. Currently available antemortem diagnostic testing has low specificity. The hypothesis of this study was that serum and cerebrospinal fluid (CSF) of horses experimentally challenged with S neurona would have an increased S neurona‐specific IgM (Sn‐IgM) concentration after infection, as determined by an IgM capture enzyme linked immunoassay (ELISA). The ELISA was based on the S neurona low molecular weight protein SNUCD‐1 antigen and the monoclonal antibody 2G5 labeled with horseradish peroxidase. The test was evaluated using serum and CSF from 12 horses experimentally infected with 1.5 million S neurona sporocysts and 16 horses experimentally infected with varying doses (100 to 100,000) of S neurona sporocysts, for which results of histopathologic examination of the central nervous system were available. For horses challenged with 1.5 million sporocysts, there was a significant increase in serum Sn‐IgM concentrations compared with values before infection at weeks 2–6 after inoculation (P < .0001). For horses inoculated with lower doses of S neurona, there were significant increases in serum Sn‐IgM concentration at various points in time after inoculation, depending on the challenge dose (P < .01). In addition, there was a significant increase between the CSF Sn‐IgM concentrations before and after inoculation (P < .0001). These results support further evaluation of the assay as a diagnostic test during the acute phase of EPM.